Microvesicle formulations used in topical drugs and cosmetics affect product efficiency, performance and allergenicity

Dermatitis

Volumn 21, Issue 5, 2010, Pages 243-247

  Madsen, Jakob Torp ^a   Andersen, Klaus Ejner ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COSMETIC; DRUG CARRIER; ETHOSOME; LIPOSOME; NANOCARRIER; NANOPARTICLE; NANOSPHERE; NIOSOME; TOPICAL AGENT; TRANSFERSOME; UNCLASSIFIED DRUG;

ACCURACY; ALLERGENICITY; DERMATITIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; HUMAN; MICROCAPSULE; MICROENCAPSULATION; MICROTECHNOLOGY; NANOEMULSION; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW; SKIN; SKIN TOXICITY;

ADMINISTRATION, TOPICAL; ALLERGENS; COSMETICS; DERMATITIS, ALLERGIC CONTACT; DOSAGE FORMS; DRUG CARRIERS; HUMANS;

EID: 77957665583     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.2310/6620.2010.10052     Document Type: Review

References (30)

1. Simon JA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006;13: 222-31, doi:10.1097/01.gme. 0000174096.56652.4f.
2. Lakshmi P, Devi G, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol 2007;73:157-61, doi:10.4103/0378-6323.32709. (Pubitemid 46918508)
3. Horwitz E, Pisanty S, Czerninski R, et al. A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:700-5, doi:10.1016/S1079-2104(99)70164-2.
4. Godin B, Touitou E, Rubinstein E, et al. A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: an in vivo study. J Antimicrob Chemother 2005;55: 989-94, doi:10.1093/jac/dki125. (Pubitemid 40883186)
5. de Leeuw J, de Vijlder HC, Bjerring P, Neumann HA. Liposomes in dermatology today. J Eur Acad Dermatol Venereol 2009;23:505-16, doi:10.1111/j.1468-3083.2009.03100.x.
6. de Leeuw J, van der Beek N, Bjerring P, Martino Neumann HA. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents. J Eur Acad Dermatol Venereol 2010;24:460-9. [Epub 2009 Sep 30], doi:10.1111/j.1468-3083. 2009.03447.x.
7. Nohynek GJ, Lademann J, Ribaud C, Roberts MS. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol 2007;37:251-77, doi:10.1080/10408440601177780. (Pubitemid 46440572)
8. Nohynek GJ, Antignac E, Re T, Toutain H. Safety assessment of personal care products/cosmetics and their ingredients. Toxicol Appl Pharmacol 2010;243:239-59, doi:10.1016/j.taap.2009.12.001.
9. Schmid M-H, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Deliv Rev 1996;18: 335-42, doi:10.1016/0169-409X(95) 00019-4.
10. Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta 2004;1663:61-73, doi:10.1016/j.bbamem. 2004.01.006. (Pubitemid 38625580)
11. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 2008;34: 203-22, doi:10.1016/j.ejps.2008.05.002.
12. Benson HA. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv 2006;3:727-37, doi:10.1517/17425247.3.6.727.
13. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996;13:257-388. (Pubitemid 27024259)
14. Godin B, Touitou E. Ethosomes: new prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst 2003;20:63-102, doi:10.1615/ CritRevTherDrugCarrierSyst.v20.i1.20. (Pubitemid 36929628)
15. Wissing SA, Muller RH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 2003;254:65-8, doi:10.1016/S0378-5173(02)00684- 1.
16. Wissing SA, Muller RH. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study. Eur J Pharm Biopharm 2003;56:67-72, doi:10.1016/S0939-6411(03)00040-7.
17. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84, doi:10.1016/j.ijpharm.2008.10.003.
18. Kotyla T, Kuo F, Moolchandani V, et al. Increased bioavailability of a transdermal application of a nano-sized emulsion preparation. Int J Pharm 2008;347:144-8, doi:10.1016/j.ijpharm.2007.06.045. (Pubitemid 350180323)
19. Izquierdo P, Wiechers JW, Escribano E, et al. A study on the influence of emulsion droplet size on the skin penetration of tetracaine. Skin Pharmacol Physiol 2007;20:263-70, doi:10.1159/000106076. (Pubitemid 47312681)
20. Sinha VR, Bansal K, Kaushik R, et al. Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm 2004;278: 1-23, doi:10.1016/j.ijpharm.2004.01.044.
21. Clemmensen A, Thormann J, Andersen KE. Allergic contact dermatitis from retinyl palmitate in polycaprolactone. Contact Dermatitis 2007;56:288-9, doi:10.1111/j.1600-0536.2006.00988.x. (Pubitemid 46624109)
22. Alvarez-Roman R, Naik A, Kalia YN, et al. Skin penetration and distribution of polymeric nanoparticles. J Control Release 2004;99: 53-62, doi:10.1016/j.jconrel.2004.06.015.
23. Alvarez-Roman R, Naik A, Kalia YN, et al. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004;21: 1818-25, doi:10.1023/B:PHAM.0000045235.86197.ef.
24. Sheihet L, Chandra P, Batheja P, et al. Tyrosine-derived nanospheres for enhanced topical skin penetration. Int J Pharm 2008; 350:312-9, doi:10.1016/j.ijpharm.2007.08.022.
25. Marston S. Propyl gallate on liposomes. Contact Dermatitis 1992; 27:74-6, doi:10.1111/j.1600-0536.1992.tb05213.x.
26. Madsen JT, Vogel S, Karlberg A, et al. Ethosome formulations of known contact allergens can increase the sensitizing capacity. Acta Derm Venereol 2010;90:374-8, doi:10.2340/00015555-0874.
27. Madsen JT, Vogel S, Karlberg A, et al. Ethosome formulation of contact allergens may enhance patch test reactions in patients. Contact Dermatitis 2010. [Submitted]
28. Tanglertsampan C, Maibach HI. The role of vehicles in diagnostic patch testing. A reappraisal. Contact Dermatitis 1993;29:169-74, doi:10.1111/j.1600- 0536.1993.tb03531.x.
29. Basketter DA, Gerberick GF, Kimber I. Skin sensitisation, vehicle effects and the local lymph node assay. Food Chem Toxicol 2001;39: 621-7, doi:10.1016/S0278-6915(00)00169-1.
30. Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 2003; 258:141-51, doi:10.1016/S0378-5173(03)00183-2.